Form 4: Vericel Corp Director Kevin McLaughlin Executes Stock Option and Sells Shares Under 10b5-1 Plan

Kevin McLaughlin, a director at Vericel Corp, exercised stock options and sold 7,000 shares of common stock at $39.98 per share on May 7, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 7, 2025, Kevin McLaughlin, a director of Vericel Corp, executed a transaction involving the company's stock.
• McLaughlin exercised a stock option to acquire 7,000 shares of common stock at a price of $2.76 per share.
• Simultaneously, McLaughlin sold 7,000 shares of common stock at a price of $39.98 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2024.
• Following these transactions, McLaughlin directly owns 15,100 shares of Vericel Corp.
• McLaughlin also holds options to purchase 7,000 shares of common stock, originally granted on May 4, 2016, which became exercisable in monthly installments.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they reflect insider trading activity, but the pre-arranged trading plan mitigates concerns about opportunistic trading.

Key Dates

Keywords

Vericel Corp, Kevin McLaughlin, stock options, Rule 10b5-1, Form 4, insider trading, VCEL, stock sale